Fig. 5: Utility of the HMGA2 test in intermediate cytogenetic risk AML patients.
From: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
a From left to right for patients of the training cohort classified in the intermediate cytogenetic risk category: overall survival (OS), relapse-free survival (RFS) and cumulative incidence of relapse (CIR) curves according to high expression levels of HMGA2 (HMGA2 + , H + ) compared with low expression levels (HMGA2−, H−). The P values were obtained by the log-rank test for comparison of OS and RFS curves and by Gray’s test for CIR curves. b Results for the six prognostically informative AML mutations (FLT3-ITD, NPM1, biallelic CEBPA, ASXL1, RUNX1, and TP53) in 41 H + patients of the training cohort classified in the intermediate cytogenetic risk category are shown. Dark blue squares, presence of mutation; light blue squares, absence of mutation (WT); white squares, sample not tested or not sequenced for this mutation (NA); H + , high expression levels of HMGA2 (≥1100 NCN)
